You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
The retinoic-acid-receptor-related orphan receptor yt (RORyt), a master regulator of the inflammatory IL-17/IL-23 cytokine axis, was recently identified as a prime drug target for many autoimmune diseases including psoriasis, multiple sclerosis, rheumatoid arthritis, asthma and COPD. In this project, Lead Pharma, Mercachem, the Laboratory for Medical Immunology, the Department of Dermatology and the Laboratory for Pediatric Infectious Diseases of the Radboud University NijmegenMedical Centre will jointly develop new in vitro and in vivo screening models that will expedite the ongoing development of new ROR?t inhibitors, and that will allow for successful and quick progression of these compounds from bench-to-bedside.
Project title: Translational models for modulators of the IL-17/IL-23 axis
Short project title: Profiling of IL-17 modulators
Principal Investigator: Dr. Sander Nabuurs
Partners: Lead Pharma, Mercachem, RUNMC
Budget: 1.1 M EUR
Start: 1 November 2012
End: 30 April 2014
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board